PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents growing 0.15% while AXSM's declined -18.83%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of AXSM's -18.83%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of AXSM's -18.80%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
≥ 1.5x AXSM's -3.18%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
≥ 1.5x AXSM's -2.21%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of AXSM's -18.61%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
50-75% of AXSM's 15.24%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
-6.71%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
Both AXSM and the company show zero Deferred Revenue (Current) Growth.
6.71%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
8.18%
Similar yoy to AXSM's 8.06%. Walter Schloss sees parallel short-term liability strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Less than half of AXSM's 0.43%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
6.04%
Above 1.5x AXSM's 2.86%. Michael Burry sees a potential leverage warning sign.
4.76%
Above 1.5x AXSM's 0.11%. Michael Burry suspects heavy new equity expansion or dilution.
-2.66%
Below half AXSM's -10.25%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of AXSM's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half AXSM's -40.20%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half AXSM's -18.61%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Less than half of AXSM's 0.00%. David Dodd sees less overall debt expansion vs. competitor.
-0.28%
Less than half of AXSM's 29.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.